Change of Macular Pigment Optical Density After Intravitreal Triamcinolon Injection Treatment in Patient with Diabetic Macular Edema

The Catholic University of Korea, Seoul St. Mary's Hospital0 个研究点目标入组 62 人开始时间: 待定最近更新: 2022年1月11日

试验速览

暂无简介。

•1. A person who meets the following criteria
•(1) a person diagnosed with diabetic and macular edema
•(2) inovolved at least one eye
•(3) central macular thickness is 300 or more by optical coherence tomography
•2. Adult, the age of twenty or more
•3. Patients with visual acuity less than or equal to 20/40 (Snellen) in the pathologic eye
•4. Patients who voluntarily decided to participate in the study and signed a consent form

•1. Pregnant state
•2. Previous vitrectomy history
•3. Previous history of intravitreal triamcinolone injection due to diabetic macular edema
•4. Macular edema caused by other than diabetes
•5. Diagnosed or treatment for other ocular cormorbidity such as, Intermediate or advanced dry age related macular degeneration (ARMD), exudative ARMD, vitreous hemorrhage, retinal vein occlusion, uveitis, retinal dystrophy, ocular trauma, optic nerve atrophy, intraocular tumor, corneal opacity
•6. Ongoing diagnosed or suspcious intraocular or periocular infection
•7. Uncontrolled glaucoma, Intraocular pressure over 21mmHg even with appropriate use of intraocular pressure lowering agents. History of glaucoma surgery due to steroid induced glaucoma
•8. Chronic alcoholics or psychiatric state that could affact the study process.
•9. Patients who thought to be not able to complete study process or have a medical condition is unsuitable for study process by clinicion's opinion
•10. Uptaking lutein or other medication which affect macular pigment optical density.

发起方